• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Mintz Steven bought $70,900 worth of shares (7,600 units at $9.33), increasing direct ownership by 230% to 10,907 units (SEC Form 4)

    6/27/24 8:26:37 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SER alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    MINTZ STEVEN

    (Last) (First) (Middle)
    601 GENOME WAY,
    SUITE 2001

    (Street)
    HUNTSVILLE AL 35806

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Serina Therapeutics, Inc. [ SER ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/21/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/21/2024 P 5,000 A $9.5 8,307 D
    Common Stock 06/25/2024 P 2,600 A $9 10,907 D
    Common Stock 9,900 I By Spouse
    Common Stock 1,240 I By Adult Child 1(1)
    Common Stock 1,240 I By Adult Child 2(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
    2. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
    /s/ Steven Mintz 06/27/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SER alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SER

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SER
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

      - Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization

      5/22/25 4:50:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

      HUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 15,000 shares of Serina's common stock to two new non-executive employees on March 20, 2025 (each, an "Option Grant"). Each Option Grant has an exercise price equal to the closing price of Serina's common stock on March 20, 2025. The Option Grants were offered as material inducement to the employees' employment. The Option Grants were appro

      5/14/25 3:15:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

      On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson's disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform across multiple therapeutic modalitiesTwo new seasoned biotech leaders added to the Board of Directors HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2025, along with recent business highlights. "We are energized by the substantial progress and strengthened foundation

      5/8/25 4:23:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Venkatesan Jay

      4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

      4/10/25 4:03:12 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bailey Gregory

      4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

      4/10/25 4:02:46 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Ledger Steven A acquired 95,730 shares (SEC Form 4)

      4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

      4/1/25 4:06:08 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

      SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

      12/9/24 4:45:59 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Serina Therapeutics Inc.

      SC 13G/A - Serina Therapeutics, Inc. (0001708599) (Subject)

      11/14/24 5:09:38 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

      SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

      7/5/24 4:01:13 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SER
    Financials

    Live finance-specific insights

    See more
    • Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

      On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson's disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform across multiple therapeutic modalitiesTwo new seasoned biotech leaders added to the Board of Directors HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2025, along with recent business highlights. "We are energized by the substantial progress and strengthened foundation

      5/8/25 4:23:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

      HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2024, along with key recent updates. Recent Highlights Partnership and Presentations with Enable Injections: Building on its collaboration with Enable Injections, Serina presented a case study at the 14th Annual Injectables Summit in Boston, MA, detailing the combination of Serina's lead candidate, SER-252 (POZ-apomorphine), w

      11/12/24 5:00:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SER
    SEC Filings

    See more
    • Serina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

      5/22/25 4:40:16 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serina Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

      5/8/25 4:12:25 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Serina Therapeutics Inc.

      10-Q - Serina Therapeutics, Inc. (0001708599) (Filer)

      5/8/25 4:10:21 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SER
    Leadership Updates

    Live Leadership Updates

    See more
    • Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

      - Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization

      5/22/25 4:50:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

      HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions. Dr. Venkatesan most recently served as Chairman, President, and CEO of Angion Biomedica until its merger with Elicio Therapeutics in 2023. He

      2/12/25 4:15:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

      HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Karen J. Wilson to the Board of Directors. "We are excited to welcome Karen to the Board of Directors. Karen's financial expertise and deep understanding of the biotech landscape will play a crucial role in guiding our strategic initiatives and delivering transformative therapies to patients," said Steve Ledger, Serina's Chief Executive Officer. Ms. Wilson brings over three decades of leadership experiences in the life sciences sector. She currently se

      1/14/25 5:25:00 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bailey Gregory bought $17,745 worth of shares (3,866 units at $4.59), increasing direct ownership by 6% to 67,243 units (SEC Form 4)

      4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

      12/19/24 4:05:12 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bailey Gregory bought $6,851 worth of shares (1,137 units at $6.03), increasing direct ownership by 2% to 63,377 units (SEC Form 4)

      4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

      9/24/24 4:30:06 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bailey Gregory bought $88,257 worth of shares (14,388 units at $6.13), increasing direct ownership by 30% to 62,240 units (SEC Form 4)

      4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

      9/20/24 6:59:29 PM ET
      $SER
      Biotechnology: Pharmaceutical Preparations
      Health Care